- Federal agenciesAllows ONDCP to fund or conduct previously prohibited research, potentially increasing federal public-health research a…
- Targeted stakeholdersMay reduce regulatory constraints, speeding policy updates and program deployment within ONDCP.
- Targeted stakeholdersCould improve evidence-based policymaking, potentially leading to more effective prevention and treatment programs.
Evidence-Based Drug Policy Act of 2025
Referred to the Committee on Oversight and Government Reform, and in addition to the Committees on Energy and Commerce, and the Judiciary, for a period to be subsequently determin…
This bill repeals Section 704(b)(12) of the Office of National Drug Control Policy Reauthorization Act of 1998.
No other language or amendments are included in the text provided.
Narrow, low-cost repeal improves prospects, but unknown content of the repealed clause and lack of compromise features create material uncertainty.
Relative to its intended legislative type, this bill is a narrowly targeted statutory repeal that is legally precise in identifying the provision to be removed but provides minimal contextual, fiscal, transitional, or oversight detail.
Liberals view repeal as enabling evidence-based public-health approaches
Who stands to gain, and who may push back.
- Permitting processRemoves a statutory safeguard, possibly permitting actions some stakeholders view as endorsing drug policy changes.
- Federal agenciesCould create legal uncertainty between federal ONDCP actions and state controlled-substance laws.
- Targeted stakeholdersMay increase regulatory burden for other agencies adjusting to changed ONDCP priorities.
Why the argument around this bill splits.
Liberals view repeal as enabling evidence-based public-health approaches
Likely supportive, viewing repeal as removing a statutory barrier to evidence-based drug treatment, harm reduction, or research.
Support hinges on the repealed subsection having limited such programs; that content is not included in the bill text.
Cautiously supportive but conditional: the repeal could promote evidence-based policymaking, but requires clarification on effects, costs, and legal consequences before full endorsement.
Likely skeptical or opposed, seeing repeal as possibly weakening statutory drug-control measures or confusing enforcement priorities; reaction depends on the unknown content of the repealed subsection.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, low-cost repeal improves prospects, but unknown content of the repealed clause and lack of compromise features create material uncertainty.
- Text of section 704(b)(12) being repealed is not included
- Whether the repealed language is ideologically or practically controversial
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Liberals view repeal as enabling evidence-based public-health approaches
Narrow, low-cost repeal improves prospects, but unknown content of the repealed clause and lack of compromise features create material unce…
Relative to its intended legislative type, this bill is a narrowly targeted statutory repeal that is legally precise in identifying the provision to be removed but provides minimal contextual, fiscal, transitional, or o…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.